Antimicrobial Therapy forHelicobacter pyloriInfection (Q41683796)

7 October 2017

1 reference

title

Antimicrobial therapy for Helicobacter pylori infection (English)

1 reference

7 October 2017

Antimicrobial Therapy forHelicobacter pyloriInfection (English)

1 reference

https://api.crossref.org/works/10.1111/J.1523-5378.1997.06B01.X

2 December 2024

1 reference

G. N. Tytgat

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A9432361

2 December 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=9432361

2 December 2024

publication date

1 July 1997

1 reference

7 October 2017

July 1997

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=9432361

full work available at URL

2 December 2024

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1523-5378.1997.06b01.x

1 reference

https://api.crossref.org/works/10.1111/J.1523-5378.1997.06B01.X

https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1523-5378.1997.06b01.x

2 December 2024

1 reference

https://api.crossref.org/works/10.1111/J.1523-5378.1997.06B01.X

2 December 2024

1 reference

7 October 2017

volume

2 Suppl 1

1 reference

7 October 2017

page(s)

S81-8

1 reference

Treatment of Helicobacter pylori Infection: A Review of the World Literature

7 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1523-5378.1997.06B01.X

Effect of varying pH on the susceptibility of Campylobacter pylori to antimicrobial agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1523-5378.1997.06B01.X

Culture of Helicobacter pylori under aerobic conditions on solid media

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1523-5378.1997.06B01.X

Redox potential and oxygen concentration as factors in the susceptibility of Helicobacter pylori to nitroheterocyclic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1523-5378.1997.06B01.X

Lansoprazole, a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity against Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1523-5378.1997.06B01.X

Potent inhibitory action of the gastric proton pump inhibitor lansoprazole against urease activity of Helicobacter pylori: unique action selective for H. pylori cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1523-5378.1997.06B01.X

Activity of lansoprazole against Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1523-5378.1997.06B01.X

Inhibitory action of lansoprazole and its analogs against Helicobacter pylori: inhibition of growth is not related to inhibition of urease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1523-5378.1997.06B01.X

How to achieve a near 100% cure rate for H. pylori infection in peptic ulcer patients. A personal viewpoint

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1523-5378.1997.06B01.X

Proposal for use of a standard side effect scoring system in studies exploring Helicobacter pylori treatment regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1523-5378.1997.06B01.X

Effect of omeprazole on the distribution of metronidazole, amoxicillin, and clarithromycin in human gastric juice

2 December 2024

1 reference

https://api.crossref.org/works/10.1111/J.1523-5378.1997.06B01.X

Effect of omeprazole on movement of intravenously administered metronidazole into gastric juice and its significance in treatment of Helicobacter pylori

2 December 2024

1 reference

https://api.crossref.org/works/10.1111/J.1523-5378.1997.06B01.X

Review article: treatments that impact favourably upon the eradication of Helicobacter pylori and ulcer recurrence

2 December 2024

1 reference

https://api.crossref.org/works/10.1111/J.1523-5378.1997.06B01.X

No effect of omeprazole-induced hypoacidity on the bioavailability of amoxycillin or bacampicillin

2 December 2024

1 reference

https://api.crossref.org/works/10.1111/J.1523-5378.1997.06B01.X

The effect of omeprazole on gastric juice viscosity, pH and bacterial counts

2 December 2024

1 reference

https://api.crossref.org/works/10.1111/J.1523-5378.1997.06B01.X

Omeprazole causes delay in gastric emptying of digestible meals

2 December 2024

1 reference

https://api.crossref.org/works/10.1111/J.1523-5378.1997.06B01.X

Metronidazole-resistant H pylori--of questionable clinical importance

2 December 2024

1 reference

https://api.crossref.org/works/10.1111/J.1523-5378.1997.06B01.X

An Increase in Helicobacter pylori Strains Resistant to Metronidazole: A Five‐Year Study

2 December 2024

1 reference

https://api.crossref.org/works/10.1111/J.1523-5378.1997.06B01.X

Short report: smoking habits and the acquisition of metronidazole resistance in patients with Helicobacter pylori-related gastritis.

2 December 2024

1 reference

https://api.crossref.org/works/10.1111/J.1523-5378.1997.06B01.X

Proposed mechanism for metronidazole resistance in Helicobacter pylori

2 December 2024

1 reference

https://api.crossref.org/works/10.1111/J.1523-5378.1997.06B01.X

Clarithromycin-amoxycillin therapy for Helicobacter pylori infection

2 December 2024

1 reference

https://api.crossref.org/works/10.1111/J.1523-5378.1997.06B01.X

Mutations in 23S rRNA are associated with clarithromycin resistance in Helicobacter pylori.

2 December 2024

1 reference

https://api.crossref.org/works/10.1111/J.1523-5378.1997.06B01.X

Acid inhibitory characteristics of omeprazole in man

2 December 2024

1 reference

https://api.crossref.org/works/10.1111/J.1523-5378.1997.06B01.X

Hitting H pylori for four

2 December 2024

1 reference

https://api.crossref.org/works/10.1111/J.1523-5378.1997.06B01.X

Rapid eradication of Helicobacter pylori infection.

2 December 2024

1 reference

https://api.crossref.org/works/10.1111/J.1523-5378.1997.06B01.X

Prevalence of metronidazole resistant Helicobacter pylori strains among Chinese peptic ulcer disease patients and normal controls in Hong Kong

2 December 2024

1 reference

https://api.crossref.org/works/10.1111/J.1523-5378.1997.06B01.X

Metronidazole, omeprazole and clarithromycin: an effective combination therapy for Helicobacter pylori infection

2 December 2024

1 reference

https://api.crossref.org/works/10.1111/J.1523-5378.1997.06B01.X

Therapeutic options after failed Helicobacter pylori eradication therapy

2 December 2024

1 reference

https://api.crossref.org/works/10.1111/J.1523-5378.1997.06B01.X

2 December 2024

Identifiers

1 reference

7 October 2017

1 reference